TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23505452

Group type: EXPERIMENTAL
Intervention: Very low energy diet for 2 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Follow-up after 10 months
Number of subjects: 28
Study: 23506003

Group type: EXPERIMENTAL
Intervention: Cortisol metabolism assessment in critically ill patients
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cortisol production measurement
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cortisol clearance measurement during tracer infusion
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cortisol clearance measurement after hydrocortisone administration
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels comparison
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cortisol response to corticotropin stimulation
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Assessment of urinary steroid ratios and liver biopsy samples
Number of subjects: 158
Study: 23506243

Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg qd, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Raltegravir 400 mg bid, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Number of subjects: 17
Study: 23506651

Group type: EXPERIMENTAL
Intervention: Pharmacist scores on the attitudes subscale regarding the implementation of hypertension intervention
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Pharmacist scores on the attitudes subscale regarding the implementation of asthma intervention
Number of subjects: 361

Group type: COMPARATOR
Intervention: Clinical pharmacy service scores
Number of subjects: 361

Group type: COMPARATOR
Intervention: TPB subscale scores
Number of subjects: 361
Study: 23508216

Group type: EXPERIMENTAL
Intervention: Patellofemoral pain syndrome (PFPS) group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no musculoskeletal pain)
Number of subjects: 57
Study: 23509310

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine) for four cycles
Number of subjects: 117
Study: 23509819

Group type: EXPERIMENTAL
Intervention: Kinematic measures during a clinical diagnostic technique
Number of subjects: 2
Study: 23510361

Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 4
Study: 23510802

Group type: EXPERIMENTAL
Intervention: cediranib 20mg
Number of subjects: 599
Study: 23511559

Group type: EXPERIMENTAL
Intervention: Sunitinib plus gemcitabine (Schedule 2/1)
Number of subjects: 44
Study: 23511678

Group type: EXPERIMENTAL
Intervention: Oxygen administration via nasal cannula at 5 L/min starting 15 minutes after SGB
Number of subjects: 38
Study: 23511841

Group type: EXPERIMENTAL
Intervention: Single-organ failure and multiorgan failure (MOF) in pediatric burn patients
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: DENVER2 score for assessing organ-specific scores
Number of subjects: 821
Study: 23511909

Group type: EXPERIMENTAL
Intervention: CNS disorders
Number of subjects: 0
Study: 23512637

Group type: EXPERIMENTAL
Intervention: EE 30 μg/LNG 150 μg qd plus empagliflozin 25 mg qd for 7 days (test; period 2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: EE 30 μg/LNG 150 μg qd for 14 days (reference; period 1)
Number of subjects: 18
Study: 23512786

Group type: COMPARATOR
Intervention: HIV/non-HCV recipients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HIV/HCV-coinfected recipients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HCV coinfection
Number of subjects: 116
Study: 23512837

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A) injection
Number of subjects: 468
Study: 23513068

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 1134
Study: 23513248

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SIMV with set breathing frequencies of ≥ 10 breaths/min
Number of subjects: 35

Group type: COMPARATOR
Intervention: Asynchronous subjects
Number of subjects: 35
Study: 23514360

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until objective tumor progression, unacceptable toxicity, death, or study discontinuation.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Number of subjects: 64
Study: 23515007

Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (highest quintiles)
Number of subjects: 491841

Group type: EXPERIMENTAL
Intervention: Intakes of legumes, whole grains, and cruciferous vegetables
Number of subjects: 491841

Group type: COMPARATOR
Intervention: Refined grain intake (comparison of quintile 5 with quintile 1)
Number of subjects: 491841
Study: 23515269

Group type: EXPERIMENTAL
Intervention: RTOG scale
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CTCAE scale
Number of subjects: 55
Study: 23515750

Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB) using 20-gauge and 18-gauge semi-automated needles; 11 procedures under ultrasound guidance.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB)
Number of subjects: 46
Study: 23515925

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 423
Study: 23516391

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of foretinib (240 mg/day for 5 days every 2 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Daily dosing of foretinib (80 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intermittent dosing of foretinib (240 mg/day)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Foretinib treatment
Number of subjects: 74
Study: 23516440

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg po daily for 24 weeks
Number of subjects: 35
Study: 23517020

Group type: EXPERIMENTAL
Intervention: Standard-dose clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 and *3 loss-of-function alleles
Number of subjects: 0
Study: 23517449

Group type: EXPERIMENTAL
Intervention: Intradermal insulin delivery using a hollow microneedle
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subcutaneous insulin delivery via insulin pump catheter
Number of subjects: 16
Study: 23517836

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 435
Study: 23517839

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting nitinol stents
Number of subjects: 108
Study: 23518189

Group type: EXPERIMENTAL
Intervention: HPV vaccine (initial dose)
Number of subjects: 68
Study: 23518218

Group type: EXPERIMENTAL
Intervention: NEVO SES
Number of subjects: 394

Group type: COMPARATOR
Intervention: TAXUS PES
Number of subjects: 394
Study: 23518262

Group type: EXPERIMENTAL
Intervention: Focal Electrically Administered Seizure Therapy (FEAST)
Number of subjects: 17
Study: 23518844

Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1262
Study: 23518869

Group type: EXPERIMENTAL
Intervention: Chart-based indicators of palliative care
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Family satisfaction
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Family-rated quality of dying
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Nurse-rated quality of dying
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Pain assessments in the last 24 hours of life
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Documentation of family conferences
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Discussion of prognosis in the first 72 hours in the ICU
Number of subjects: 3065
Study: 23518928

Group type: EXPERIMENTAL
Intervention: TSPYL5 SNPs (rs1864729, rs2583506)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: TSPYL5 knockdown
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: TSPYL5 overexpression
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: LCLs with variant TSPYL5 SNP genotypes
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Chromatin immunoprecipitation assay
Number of subjects: 772
Study: 23519018

Group type: EXPERIMENTAL
Intervention: TCR transgenic T cells targeted against MART-1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: TCR-engineered ACT immunotherapy
Number of subjects: 3
Study: 23519644

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention ('Obeldicks' program)
Number of subjects: 454
Study: 23519724

Group type: EXPERIMENTAL
Intervention: air-Q ILA size 1.0
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: air-Q ILA size 1.5
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: air-Q ILA size 2.0
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: air-Q ILA size 2.5
Number of subjects: 110
Study: 23520042

Group type: EXPERIMENTAL
Intervention: Semi-automated method for segmentation of renal cysts using morphologic watershed technique with shape-detection level set.
Number of subjects: 20
Study: 23520311

Group type: EXPERIMENTAL
Intervention: 500 mg clarithromycin once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin once daily
Number of subjects: 5
Study: 23520321

Group type: EXPERIMENTAL
Intervention: Sit-to-stand test
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Handgrip strength test
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Sit-to-stand test and handgrip strength test
Number of subjects: 409
Study: 23522299

Group type: EXPERIMENTAL
Intervention: Template-assisted transperineal prostate biopsy (TTPB)
Number of subjects: 87
Study: 23522337

Group type: EXPERIMENTAL
Intervention: Weight-loss intervention through a 16-week supervised diet program including formula products and dietetic counselling.
Number of subjects: 169
Study: 23522439

Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Surgical management (SM)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Surgical management with ischemia
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Procalcitonin as a risk factor
Number of subjects: 166
Study: 23523454

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 5130
Study: 23523460

Group type: EXPERIMENTAL
Intervention: Mechanical recanalization using a Solitaire FR revascularization device
Number of subjects: 40
Study: 23523668

Group type: EXPERIMENTAL
Intervention: High AREE tertile (activity related energy expenditure)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Middle AREE tertile
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low AREE tertile
Number of subjects: 82

Group type: COMPARATOR
Intervention: Female participants
Number of subjects: 82
Study: 23524045

Group type: EXPERIMENTAL
Intervention: Disconnect-reconnect technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Push-pull technique
Number of subjects: 0
Study: 23524640

Group type: EXPERIMENTAL
Intervention: T-replete second SCT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-SCT treatments
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non retransplanted patients
Number of subjects: 59
Study: 23524863

Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 0
Study: 23525305

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like strain vaccination
Number of subjects: 138
Study: 23525420

Group type: EXPERIMENTAL
Intervention: ICD shocks for adjudicated ventricular tachyarrhythmias
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Total mortality
Number of subjects: 1177
Study: 23525441

Group type: EXPERIMENTAL
Intervention: Squalene concentrations in women
Number of subjects: 2616

Group type: EXPERIMENTAL
Intervention: Squalene concentrations in men
Number of subjects: 2616

Group type: COMPARATOR
Intervention: Cholesterol absorption markers
Number of subjects: 2616
Study: 23525751

Group type: EXPERIMENTAL
Intervention: Treatment for acute ACL tear, specific intervention details not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific details not available.
Number of subjects: 0
Study: 23526734

Group type: EXPERIMENTAL
Intervention: SPECT/CT guided LM/SL
Number of subjects: 14

Group type: COMPARATOR
Intervention: LM/SL plus SPECT/CT
Number of subjects: 14
Study: 23527091

Group type: EXPERIMENTAL
Intervention: M2e-VLPs containing nucleic acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted M2e-VLPs containing nucleic acid-binding domain
Number of subjects: 0

Group type: COMPARATOR
Intervention: M2e-VLPs with or without nucleic acids
Number of subjects: 0
Study: 23529375

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with radiotherapy and temozolomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23530004

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 23530011

Group type: EXPERIMENTAL
Intervention: Chronic cannabis smoking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 23530013

Group type: EXPERIMENTAL
Intervention: Diet alone (presurgery period)
Number of subjects: 10

Group type: COMPARATOR
Intervention: RYGB surgery with daily matched diet (postsurgery period)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both periods (primary outcome)
Number of subjects: 10
Study: 23530485

Group type: EXPERIMENTAL
Intervention: High-frequency morphology index (HFMI) on admission ECG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-frequency morphology index (HFMI) post intervention ECG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-frequency morphology index (HFMI) at 24h ECG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Change in HFMI from admission ECG to 24h ECG
Number of subjects: 30
Study: 23530572

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-FU derivatives (specific regimens not detailed)
Number of subjects: 2128
Study: 23530577

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 0
Study: 23530663

Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) administered as a 1 hour IV infusion, once weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) at doses escalating from 7 to 259 mg/m(2).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) at 200 mg/m(2) given IV at Days 1, 8, and 15 every 4 weeks.
Number of subjects: 53
Study: 23530709

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 130
Study: 23530817

Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Mini Asthma Quality of Life Questionnaire (Mini-AQLQ)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Morisky Medication Adherence Scale (MMAS-4)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Treatment strategies and associated healthcare costs
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Uncontrolled/poorly controlled asthma patients
Number of subjects: 8000
Study: 23531228

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 75
Study: 23531361

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g·kg-1 body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.045 g·kg-1 body mass NaCl)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 23532529

Group type: EXPERIMENTAL
Intervention: Average RNFL thickness
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Inferior hemisphere average thickness
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Inferior quadrant average thickness
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Vertical cup-to-disc ratio
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Rim area
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Rim volume
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: GCC average thickness
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: GCC inferior thickness
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: GCC superior thickness
Number of subjects: 142
Study: 23533013

Group type: EXPERIMENTAL
Intervention: AMB-Home (nurse-led in-home cognitive behavioral program)
Number of subjects: 194
Study: 23533230

Group type: EXPERIMENTAL
Intervention: Cixutumumab plus androgen deprivation therapy (ADT) consisting of bicalutamide and goserelin for 13 weeks before prostatectomy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 29
Study: 23533264

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 3
Study: 23535095

Group type: EXPERIMENTAL
Intervention: Oral desensitization protocol (200 mL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (19 children)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral desensitization protocol
Number of subjects: 36
Study: 23535105

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 8 weeks followed by 44 weeks of weight maintenance
Number of subjects: 91
Study: 23535761

Group type: EXPERIMENTAL
Intervention: Prucalopride 0.03 mg/kg single dose
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prucalopride 0.01 to 0.03 mg/kg once daily for 8 weeks
Number of subjects: 38
Study: 23535954

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg + radiotherapy (8 Gy/lesion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg - Monotherapy
Number of subjects: 50
Study: 23536265

Group type: EXPERIMENTAL
Intervention: CKD group
Number of subjects: 287

Group type: COMPARATOR
Intervention: Non-CKD group
Number of subjects: 287
Study: 23536386

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodialysis (CVVHD)
Number of subjects: 20
Study: 23536883

Group type: EXPERIMENTAL
Intervention: Diet counseling provision
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Dentist characteristics associated with diet counseling
Number of subjects: 282
Study: 23536999

Group type: EXPERIMENTAL
Intervention: Sagittal Abdominal Diameter (SAD)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (apoB)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Total cholesterol or LDL-cholesterol
Number of subjects: 255
Study: 23537041

Group type: COMPARATOR
Intervention: Lixisenatide (10 weeks treatment after ischemia-reperfusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lixisenatide (acute treatment during ischemia-reperfusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lixisenatide (in isolated cardiomyocytes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lixisenatide (chronic treatment)
Number of subjects: 0
Study: 23537121

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) and systemic antibiotics
Number of subjects: 29
Study: 23537365

Group type: EXPERIMENTAL
Intervention: Low-dose LPS inhalation (2 μg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Roflumilast treatment (5 days) before last LPS challenge
Number of subjects: 12
Study: 23537458

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: sitagliptin 100 mg
Number of subjects: 0
Study: 23537966

Group type: EXPERIMENTAL
Intervention: Bendavia at 0.05 mg/kg per hour
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (identically appearing) administered as an intravenous infusion at 60 mL/h
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bendavia
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 23537969

Group type: EXPERIMENTAL
Intervention: Parachute device implantation
Number of subjects: 478

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 478
Study: 23537971

Group type: EXPERIMENTAL
Intervention: Fetal middle cerebral artery pulsatility index (MCA-PI) z-scores
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Fetal cerebrovascular resistance (lower MCA-PI z-scores)
Number of subjects: 230
Study: 23537968

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT) + standard therapy
Number of subjects: 692

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: PCDT + standard therapy
Number of subjects: 692
Study: 23538093

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) increase
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: New embolic events in DW-MRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Neurological deficit assessed by NIHSS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Plasma levels of NSE and new emboli in DW-MRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Impact of concomitant comorbidities
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Self-sufficiency and all-cause mortality after 30 days and one year
Number of subjects: 61
Study: 23538524

Group type: EXPERIMENTAL
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 193
Study: 23538866

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy (CT)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: EGFR-TKIs
Number of subjects: 353
Study: 23539736

Group type: EXPERIMENTAL
Intervention: 1-hour OGTT glucose of >155 mg/dL
Number of subjects: 474
Study: 23541126

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5-225 mg/d)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotype
Number of subjects: 865
Study: 23541189

Group type: EXPERIMENTAL
Intervention: Lurasidone (40-120 mg/d)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Olanzapine (15 mg)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254